drugset
drugset / Trial / NCT06022276

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

NCT06022276 ↗

Unknown 46 enrolled Tianjin Medical University Second Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of nimotuzumab in the treatment of EGFR-amplified advanced pan solid tumors (Lung/Esophageal/Gastric/Pancreatic /Colorectal / Head and neck Cervical).

Timeline

Start
2022-12-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 400 mg —

Indications

cancer